1281 related articles for article (PubMed ID: 17868356)
1. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
Mathew NT; Kailasam J; Meadors L
Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type A for the treatment of nummular headache: four case studies.
Mathew NT; Kailasam J; Meadors L
Headache; 2008 Mar; 48(3):442-7. PubMed ID: 18028377
[TBL] [Abstract][Full Text] [Related]
6. Headache prophylaxis with BoNTA: patient characteristics.
Silberstein SD; Marmura MJ; Shaw J; Yu S
Headache; 2010 Jan; 50(1):63-70. PubMed ID: 19549156
[TBL] [Abstract][Full Text] [Related]
7. Duration of migraine is a predictor for response to botulinum toxin type A.
Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW
Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
Blumenfeld AM; Schim JD; Chippendale TJ
Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study.
Harden RN; Cottrill J; Gagnon CM; Smitherman TA; Weinland SR; Tann B; Joseph P; Lee TS; Houle TT
Headache; 2009 May; 49(5):732-43. PubMed ID: 19178577
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.
Silberstein SD; Göbel H; Jensen R; Elkind AH; Degryse R; Walcott JM; Turkel C
Cephalalgia; 2006 Jul; 26(7):790-800. PubMed ID: 16776693
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
Saper JR; Mathew NT; Loder EW; DeGryse R; VanDenburgh AM;
Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study.
Schulte-Mattler WJ; Krack P;
Pain; 2004 May; 109(1-2):110-4. PubMed ID: 15082132
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin A injection into corrugator muscle for frontally localised chronic daily headache or chronic tension-type headache.
de Ru JA; Buwalda J
J Laryngol Otol; 2009 Apr; 123(4):412-7. PubMed ID: 18588738
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin in tension-type headache.
Relja M; Telarović S
J Neurol; 2004 Feb; 251 Suppl 1():I12-4. PubMed ID: 14991337
[TBL] [Abstract][Full Text] [Related]
15. Myofascial trigger points and their relationship to headache clinical parameters in chronic tension-type headache.
Fernández-de-Las-Peñas C; Alonso-Blanco C; Cuadrado ML; Gerwin RD; Pareja JA
Headache; 2006 Sep; 46(8):1264-72. PubMed ID: 16942471
[TBL] [Abstract][Full Text] [Related]
16. Increased pericranial tenderness, decreased pressure pain threshold, and headache clinical parameters in chronic tension-type headache patients.
Fernández-de-Las-Peñas C; Cuadrado ML; Arendt-Nielsen L; Ge HY; Pareja JA
Clin J Pain; 2007 May; 23(4):346-52. PubMed ID: 17449996
[TBL] [Abstract][Full Text] [Related]
17. The local and referred pain from myofascial trigger points in the temporalis muscle contributes to pain profile in chronic tension-type headache.
Fernández-de-Las-Peñas C; Ge HY; Arendt-Nielsen L; Cuadrado ML; Pareja JA
Clin J Pain; 2007; 23(9):786-92. PubMed ID: 18075406
[TBL] [Abstract][Full Text] [Related]
18. A comparative analysis of personality profile and muscle tenderness between chronic migraine and chronic tension-type headache.
Mongini F; Rota E; Deregibus A; Mura F; Francia Germani A; Mongini T
Neurol Sci; 2005 Oct; 26(4):203-7. PubMed ID: 16193246
[TBL] [Abstract][Full Text] [Related]
19. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases.
Tepper SJ; Bigal ME; Sheftell FD; Rapoport AM
Headache; 2004 Sep; 44(8):794-800. PubMed ID: 15330826
[TBL] [Abstract][Full Text] [Related]
20. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
Relja M; Poole AC; Schoenen J; Pascual J; Lei X; Thompson C;
Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
